Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold-Reference-Cited by-同舟云学术

Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold

Published:2024-02-13 Issue:4 Volume:67 Page:2379-2396
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lescop Cyrille¹,Brotschi Christine¹,Williams Jodi T.¹^ORCID,Sager Christoph P.¹^ORCID,Birker Magdalena²,Morrison Keith³,Froidevaux Sylvie³,Delahaye Stéphane⁴,Nayler Oliver²,Bolli Martin H.¹^ORCID

Affiliation:

1. DD Chemistry, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland

2. DD Biology, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland

3. DD Pharmacology, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland

4. Preclinical DMPK, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c01826

Reference86 articles.

1. Two pathways for lysophosphatidic acid production

2. Serum Lysophosphatidic Acid Is Produced through Diverse Phospholipase Pathways

3. Regulation of Mammalian Physiology, Development, and Disease by the Sphingosine 1-Phosphate and Lysophosphatidic Acid Receptors

4. The Autotaxin–LPA Axis Emerges as a Novel Regulator of Lymphocyte Homing and Inflammation

5. Lysophosphatidic acid signalling in development

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics of Fipaxalparant, a Small‐Molecule Selective Negative Allosteric Modulator of Lysophosphatidic Acid Receptor 1, and the Effect of Food in Healthy Volunteers;Clinical Pharmacology in Drug Development;2024-05-17